Michael M. Nolan, AMRI’s senior vice president and chief financial officer, is leaving the company. Felicia Ladin will take over the role, effective February 4, 2015. Mr. Nolan will remain through February to support the transition.
 
Ms. Ladin, a CPA, brings more than 20 years of finance, accounting and tax management experience, and has spent the majority of her career in the pharma industry. Most recently, she was senior vice president, chief financial officer, Global Specialty Medicines at Teva Pharmaceuticals, USA, and from 2002 to 2014, Ms. Ladin held positions of increasing responsibility, directing financial planning and analysis operations, and serving as tax director for the U.S.
 
“We appreciate Mike’s contributions to AMRI’s growth, and I know I speak for the management team and Board of Directors in wishing him success with his future endeavors,” said William S. Marth, AMRI’s president and chief executive officer. “I am pleased that Felicia will be joining the AMRI team at this important time for the company,” continued Mr. Marth. “As we continue to build and integrate our business, Felicia’s strong track record of building global finance infrastructures and teams will be a tremendous addition to AMRI.”